Percutaneous transluminal septal myocardial ablation

Abstract

Percutaneous transluminal septal myocardial ablation (PTSMA) is a new, investigational, catheter-based treatment for severely symptomatic, medically refractory hypertrophic obstructive cardiomyopathy. A balloon catheter is used to cannulate and isolate the first or second septal perforator coronary artery. Following balloon inflation and intracoronary myocardial contrast echocardiography, ethyl alcohol is injected through the catheter lumen to cause proximal interventricular septum infarction and relief of outflow tract obstruction with improved patient symptoms. Septal scarring and thinning with reductions in the outflow tract gradients ensues over the following 6 to 12 weeks. Most patients have symptomatic improvement, at least moderate reductions in outflow tract gradients, and possibly improvement in exercise capacity. The most common procedural complication is the development of high-grade atrioventricular block necessitating implantation of a permanent pacemaker in 25% of patients. Compared with surgical myectomy, PTSMA has the advantage of being minimally invasive, easily repeated, and with relatively low major morbidity/mortality risk for patients with comorbid conditions. The findings from recently initiated international registries will be helpful in assessing the overall success and complication rates with PTSMA.